ARTICLE
15 November 2023

PE Firms On FTC And DOJ's Naughty List?

AV
Axinn Veltrop & Harkrider

Contributor

Incisive. Inclusive. Invested. We’re Axinn.

Experienced, tenacious, and always trial-ready, we are committed to understanding complex legal challenges that impact the future of our clients’ businesses, globally.

Focusing on antitrust, intellectual property, and high-stakes litigation, our extensive teams in the U.S. possess deep knowledge and client-side experience across a range of sectors, including technology, healthcare, life sciences, and consumer products.

With a strong culture of diversity, equity, and inclusion, we build relationships with our clients and colleagues alike, helping communities and acting with purpose. Our client service, entrepreneurialism, and inquisitive nature sit at the heart of the firm, enabling us to prioritize client goals and achieve successful outcomes.

The FTC and DOJ have continued their efforts to take action against private equity firms for engaging in serial acquisitions (so-called "roll-ups"). The agencies claim that these deals increase...
United States Corporate/Commercial Law

The FTC and DOJ have continued their efforts to take action against private equity firms for engaging in serial acquisitions (so-called "roll-ups"). The agencies claim that these deals increase prices and degrade quality for consumers, while allowing the investor groups to profit. The FTC's latest private equity merger case, against US Anesthesia Partners and Welsh Carson, will be a critical test of the agencies' new draft merger guidelines and their stated positions against these types of deals: specifically, "Mergers Should Not Further a Trend Toward Concentration" (Guideline 8) and "When a Merger is Part of a Series of Multiple Acquisitions, the Agencies May Examine the Whole Series" (Guideline 9).

As highlighted in a chapter of a forthcoming book, challenges to PE-backed M&A transactions are not the only aspect of the agencies' focus on private equity. This year, the DOJ Antitrust Division has expanded its lens to examine investment funds' representations on competing companies' boards under Section 8 of the Clayton Act, and DOJ has raised questions around inappropriate information sharing between competitors that could arise from such "interlocking" directors. The article linked below, featured in the forthcoming book "Women in Antitrust: Antitrust Across the Borders" (available via Amazon on November 8) provides a primer on the latest developments in Section 8 activity, and the importance of antitrust compliance for firms with board seats.

https://www.axinn.com/assets/htmldocuments/PEHUB_Clayton%20Ac_FEB23.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More